Integra LifeSciences Holdings (IART)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	81,069	116,419	156,606	204,357	213,894	201,473	193,465	186,714	214,677	201,806	192,529	149,356	93,520	81,011	11,991	46,723	60,104	58,213	96,746	73,094
Revenue (ttm)	US$ in thousands	1,486,381	1,488,778	1,493,656	1,509,844	1,505,291	1,519,581	1,519,648	1,510,233	1,535,982	1,529,270	1,504,267	1,371,086	1,317,264	1,323,744	1,339,441	1,466,719	1,476,695	1,464,883	1,451,126	1,428,751
Pretax margin		5.45%	7.82%	10.48%	13.53%	14.21%	13.26%	12.73%	12.36%	13.98%	13.20%	12.80%	10.89%	7.10%	6.12%	0.90%	3.19%	4.07%	3.97%	6.67%	5.12%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $81,069K ÷ $1,486,381K
= 5.45%

Integra Lifesciences Holdings Corp's pretax margin has shown a decreasing trend in recent quarters. In Q4 2023, the pretax margin decreased to 5.26% from 7.55% in the previous quarter Q3 2023. This downward trend is consistent with the company's performance over the last year, as seen in the decreasing pretax margins from Q4 2022 (13.73%) to Q1 2023 (13.08%).

The pretax margin measures the company's efficiency in generating profits before taxes relative to its revenue. The decreasing trend in pretax margin could indicate challenges in cost management, pricing strategy, or changes in revenue that are impacting the company's profitability.

It is essential for Integra Lifesciences Holdings Corp to closely monitor its cost structure and revenue generation strategies to maintain and improve its profitability in the future. Further analysis and investigation into the factors contributing to the declining pretax margin are necessary to develop effective strategies for improvement.